$CRIS

CURIS INC (CRIS): Submission of Matters to a Vote of Security Holders

CURIS INC (CRIS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cris-20260625 0001108205 false 0001108205 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date

Original reporting
Published Jun 25, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 8:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$CRIS
Neutral
medium confidence
Mentioned
$CRIS
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CRISNeutralLow
01

Why it matters

Because Proposal 1 passed, Curis has shareholder authorization to implement a reverse split within a broad 1-for-5 to 1-for-25 range, which can affect per-share price, liquidity, and investor perception.

02

Market read

This is a concrete corporate-action authorization event (reverse split) with immediate sentiment implications, but no execution details in the filing.

03

What to watch

Traders should watch for the board’s eventual chosen reverse-split ratio and any related financing/compliance disclosures, which are not included here.

Relevance 6/10Novelty 5/10Timing: after-hours/filing today following the June 25 special meeting vote

Background

The company held a special stockholder meeting to vote on charter amendments tied to a potential reverse stock split and an adjournment contingency.

Company-level read

Ticker impact

$CRISNeutralMedium confidence
Context

Curis reported special-meeting voting results approving a reverse stock split amendment (1-for-5 to 1-for-25) and an adjournment proposal.

Expected impact

Likely modest, two-sided reaction: reduced dilution/RSK stigma may help compliance optics, but reverse splits can pressure sentiment.

Evidence & confidence

The filing discloses the vote outcome and the reverse-split range, but provides no immediate execution date, ratio selection, or financial guidance.

Market effects

Limited read-across; reverse-split mechanics are company-specific and typically reflect listing/financing optics rather than sector fundamentals.

None material beyond US small-cap sentiment.

None.

Counterpoint

Approval alone may not change fundamentals until the board selects an exact ratio and implements the split; near-term trading could fade quickly.

Key entities

  • Curis, Inc.

    Nasdaq-listed issuer that submitted the 8-K reporting special-meeting voting results.

  • Proposal 1

    Amendments to the Restated Certificate of Incorporation to effect a reverse stock split at a board-determined ratio between 1-for-5 and 1-for-25.

  • Proposal 2

    Adjournment proposal to solicit additional proxies if Proposal 1 lacked sufficient votes.

Related articles

$CRISMedAI 8/10

Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

$CRISMed

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

$CRISMedAI 8/10

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.

$CRISMedAI 8/10

Curis stock jumps 11% on positive emavusertib trial data By Investing.com

Curis, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.

$LULULow

Lululemon Founder's $6.1B Fortune Thrown Into Chaos as He Divorces Wife of 20 Years With No Prenup

Lululemon founder Chip Wilson, estimated to have a $6.1B fortune, is divorcing his wife of 20 years without a prenuptial agreement. Under British Columbia law, their assets, including Wilson's 8.6% stake in Lululemon and 18% stake in Amer Sports, could be divided equally. The divorce may impact Lululemon's share price and market volatility, with analysts watching closely.

$ATOMed

Frisco Atmos customers to see higher gas bills in October

Atmos Energy (ATO) will raise customer rates in Frisco starting October 1, following a negotiated settlement with the Atmos Cities Steering Committee. The settlement allows for $260.5M in additional revenue, resulting in a 14.15% increase for residential customers and a 9.9% increase for commercial customers.